Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10

Suppresses Inflammation and Immune Activation Without Lymphocyte Stimulation

APVO : 4.70 (+2.40%)
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

ARWR : 15.88 (+0.51%)
APVO : 4.70 (+2.40%)
Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue

APVO : 4.70 (+2.40%)
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 4.70 (+2.40%)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?

On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.

ADVM : 5.18 (-0.38%)
HZNP : 17.02 (-0.29%)
APVO : 4.70 (+2.40%)
CLVS : 46.03 (+0.20%)
What's in the Cards for Inovio (INO) This Earnings Season?

Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

ADVM : 5.18 (-0.38%)
ARRY : 17.11 (+0.47%)
APVO : 4.70 (+2.40%)
INO : 4.18 (+1.21%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

CLDX : 0.51 (unch)
ARRY : 17.11 (+0.47%)
APVO : 4.70 (+2.40%)
BMY : 56.46 (+0.05%)
What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

ARRY : 17.11 (+0.47%)
APVO : 4.70 (+2.40%)
JNJ : 129.00 (+3.46%)
GERN : 3.58 (+4.07%)
What's in the Cards for Merrimack (MACK) in Q1 Earnings?

Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

ADVM : 5.18 (-0.38%)
ARRY : 17.11 (+0.47%)
APVO : 4.70 (+2.40%)
MACK : 5.32 (+0.37%)
Aptevo Therapeutics Announces IND Submission for APVO436

New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing

APVO : 4.70 (+2.40%)
Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natus Medical Incorporated...

REV : 16.95 (unch)
APVO : 4.70 (+2.40%)
SLGN : 26.51 (-0.38%)
BABY : 32.10 (-0.16%)
RECN : 17.05 (-0.87%)
TRST : 8.95 (unch)
Aptevo Therapeutics' Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific...

APVO : 4.70 (+2.40%)
Research Report Identifies Ambarella, Merit Medical, NETGEAR, Independent Bank, Cutera, and Aptevo Therapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ambarella, Inc. (NASDAQ:AMBA),...

INDB : 80.00 (+0.76%)
MMSI : 56.30 (+1.26%)
AMBA : 38.31 (+1.83%)
NTGR : 77.65 (-0.06%)
APVO : 4.70 (+2.40%)
CUTR : 43.60 (+1.40%)
Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update

Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million

APVO : 4.70 (+2.40%)
Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY

Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America

APVO : 4.70 (+2.40%)
Aptevo Therapeutics to Present at the 30th Annual ROTH Conference

Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 Annual ROTH...

APVO : 4.70 (+2.40%)
Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma

Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has commenced patient dosing in a Phase 2 clinical...

APVO : 4.70 (+2.40%)
Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

Strengthened Cash Position to Support Ongoing R&D and Commercial Activities;

APVO : 4.70 (+2.40%)
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

APVO : 4.70 (+2.40%)
EBS : 54.01 (+0.19%)
GSK : 41.22 (+0.05%)
SNY : 41.95 (+0.48%)
Aptevo Therapeutics Presents New Preclinical Data on APVO436 - a Next Generation ADAPTIR(TM) Bispecific Antibody Candidate

New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors

APVO : 4.70 (+2.40%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.36 , FTNT +0.58 , CAKE -0.19 , PLT -0.20 , AEO +0.28
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are currently 3 to 4 cents higher after posting fractional to 2 cent gains in most contracts to start the week. Preliminary open interest was down 3,350 contracts yesterday, suggesting short covering. The USDA Export Inspections report s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar